Patents by Inventor Peter Habenberger

Peter Habenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA
    Publication number: 20150329537
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: November 19, 2015
    Applicants: LEADDISCOVERY CENTER GMBH, MAX-PLANCK GESELLSCHAFTZUR FORDERUNG DER WIS SENSCHAFTEN E.V
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • CDK9 INHIBITORS IN THE TREATMENT OF MIDLINE CARCINOMA
    Publication number: 20140303167
    Abstract: The present invention relates to a CDK9 inhibitor, especially a selective CDK9 inhibitor, for use in treating, ameliorating and/or preventing midline carcinoma. Also corresponding methods for treating, preventing or ameliorating midline carcinoma are subject of the present invention. Preferably, NUT midline carcinoma is treated with the CDK9 inhibitors in accordance with the present invention.
    Type: Application
    Filed: August 22, 2012
    Publication date: October 9, 2014
    Applicant: LEAD DISCOVERY CENTER GMBH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • SUSCEPTIBILITY TO SELECTIVE CDK9 INHIBITORS
    Publication number: 20140287454
    Abstract: The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to a selective CDK9 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with a selective CDK9 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to a selective CDK9 inhibitor, whereby the patient is suspected to suffer from NUT midline carcinoma (NMC). The present invention also relates to a method of monitoring or predicting the efficacy of a treatment of NUT midline carcinoma (NMC), wherein treatment with a selective CDK9 inhibitor is in particular envisaged. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one rearrangement in the NUT gene for screening and/or validation of a medicament for the treatment NUT midline carcinoma (NMC) is described.
    Type: Application
    Filed: August 22, 2012
    Publication date: September 25, 2014
    Applicants: MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V., LEAD DISCOVERY CENTER GmbH
    Inventors: Axel Choidas, Bert Klebl, Peter Habenberger, Jan Eickhoff, Roman Thomas, Johannes Heuckmann
  • Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
    Patent number: 8084457
    Abstract: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: December 27, 2011
    Assignees: Lead Discovery Center GmbH, Bayer Pharma AG
    Inventors: Axel Choidas, Alexander Backes, Matt Cotten, Ola Engkvist, Beatrice Felber, Achim Freisleben, Klaus Godl, Zoltán Greff, Peter Habenberger, Doris Hafenbradl, Christian Hartung, Thomas Herget, Edmund Hoppe, Bert Klebl, Andrea Missio, Gerhard Müller, Wilfried Schwab, Birgit Zech, Jose Bravo, John Harris, Joelle Le, Jackie Macritchie, Vladimir Savic, Brad Sherborne, Don Simpson
  • Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
    Publication number: 20070191344
    Abstract: The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: September 15, 2004
    Publication date: August 16, 2007
    Inventors: Axel Choidas, Alexander Backes, Matt Cotten, Ola Engkvist, Beatrice Felber, Achim Freisleben, Klaus Godl, Zoltan Greff, Peter Habenberger, Doris Hafenbradl, Christian Hartung, Thomas Herget, Edmund Hoppe, Bert Klebl, Andrea Missio, Gerhard Muller, Wilfried Schwab, Birgit Zech, Jose Bravo, John Harris, Joelle Le, Jackie Macritchie, Vladimir Savic, Brad Sherborne, Don Simpson
  • Cellular kinases involved in Cytomegalovirus infection and their inhibition
    Patent number: 6849409
    Abstract: The role of certain cellular kinases active during Human Cytomegalovirus infection is disclosed. These cellular kinases are useful to detect HCMV infection, and can be used to screen for cellular kinase inhibitors. Cellular kinases inhibitors, which effectively downregulate these key cellular components, serve as effective therapeutics against HCMV infection.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: February 1, 2005
    Assignee: Axxima Pharmaceuticals AG
    Inventors: Daniel Schubart, Peter Habenberger, Matthias Stein-Gerlach, Dorian Bevec
  • HBV vectors and cells for producing the same
    Patent number: 6623951
    Abstract: This invention relates to an HBV vector in which functional genes of HBV are at least partially deleted. In addition, this invention concerns a process for producing such an HBV vector as well as cells usable for this purpose.
    Type: Grant
    Filed: March 2, 1998
    Date of Patent: September 23, 2003
    Assignee: MondoGen GmbH
    Inventors: Peter Hofschneider, Peter Habenberger, Ludwig Weiss
  • Cellular kinases involved in Cytomegalovirus infection and their inhibition
    Publication number: 20030082519
    Abstract: The role of certain cellular kinases active during Human Cytomegalovirus infection is disclosed. These cellular kinases are useful to detect HCMV infection, and can be used to screen for cellular kinase inhibitors. Cellular kinases inhibitors, which effectively downregulate these key cellular components, serve as effective therapeutics against HCMV infection.
    Type: Application
    Filed: October 16, 2001
    Publication date: May 1, 2003
    Inventors: Daniel Schubart, Peter Habenberger, Matthias Stein-Gerlach, Dorian Bevec